MedTrace Logo

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

NCT00004583 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2009-02-20

No results posted yet for this study

Summary

The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus. This study will compare the new PI combination of ABT-378 plus ritonavir (RTV) with another PI, nelfinavir (NFV).

Earlier studies suggest ABT-378/RTV will be just as good as and perhaps better than NFV at fighting HIV infection.

Conditions

  • HIV Infections

Interventions

DRUG

Lopinavir/Ritonavir

DRUG

Nelfinavir mesylate

DRUG

Lamivudine

DRUG

Stavudine

Sponsors & Collaborators

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Canada
  • Denmark
  • France
  • Germany
  • Poland
  • Puerto Rico
  • South Africa
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004583 on ClinicalTrials.gov